References

1 N Juteau et al, The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction, International Angiology, Sept 1995; 14(3): 8-13
2 G Jantet et al, Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study, Angiology, 2002, 53: 245-256
3 Y Vyacheslav et al, Benefits of MPFF on primary chronic venous disease-related symptoms and quality of life: the DELTA study, Phlebolymphology, 2014; 21(3): 146-151
4 A Ramelet, Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency, Angiology, Aug 2001; 52(1): S49-56
5 MJ Martinez-Zapata, et al. Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
6 Y Tsouderos, Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg, Zeitschrift Fur Kardiologie, 1991; 80 Suppl 7:95-101
7 M Duchene et al, Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the

study of Daflon 500 mg, International Angiology, Apr-Jun 1988; 7(2): 25-32
8 Y Vyacheslav et al, Benefits of MPFF on primary chronic venous disease-related symptoms and quality of life: the DELTA study, Phlebolymphology, 2014; 21(3): 146-151
9 A Ramelet, Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency, Angiology, Aug 2001; 52(1): S49-56
10 MJ Martinez-Zapata, et al. Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
11 Y Tsouderos, Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg, Zeitschrift Fur Kardiologie, 1991; 80 Suppl 7:95-101
12 M Duchene et al, Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg, International Angiology, Apr-Jun 1988; 7(2): 25-32
13 G Jantet et al, Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study, Angiology, 2002, 53: 245-256
14 G Jantet et al, Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study, Angiology, 2002, 53: 245-256
15 G Jantet et al, Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study, Angiology, 2002, 53: 245-256
16 Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology. 2000 Jan;51(1):25-9. PubMed PMID: 10667640.
17 Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology. 2000 Jan;51(1):25-9. PubMed PMID: 10667640.
18 A Ramelet, Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency, Angiology, Aug 2001; 52(1): S49-56
19 Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res. 1999;36 Suppl 1:37-41. Review. PubMed PMID: 10474049.
20 A Ramelet, Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency, Angiology, Aug 2001; 52(1): S49-56
21 Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res. 1999;36 Suppl 1:37-41. Review. PubMed PMID: 10474049.
22 Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009 Jul;7(3):303-8. Review. PubMed PMID: 19601855.
23 A Ramelet, Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency, Angiology, Aug 2001; 52(1): S49-56
24 Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009 Jul;7(3):303-8. Review. PubMed PMID: 19601855.
25 Ting AC, et al. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy. Vasc Surg. 2001 Nov-Dec;35(6):443-7. PubMed PMID: 16222383.
26 Aesculus hippocastanum (Horse chestnut). Monograph, Alternative Medicine Review. Vol 14, Number 3, 2009
27 Mrwa U, et al. Calcium-requirement for activation of skinned vascular smooth muscle from spontaneously hypertensive (SHRSP) and normotensive control rats. Life Sci. 1986 Jan 13;38(2):191-6. PubMed PMID: 3945163.
28 Aesculus hippocastanum (Horse chestnut). Monograph, Alternative Medicine Review. Vol 14, Number 3, 2009
29 Aesculus hippocastanum (Horse chestnut). Monograph, Alternative Medicine Review. Vol 14, Number 3, 2009
30 Suter A, Bommer S, Rechner J. Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: a review of 5 clinical studies. Adv Ther. 2006 Jan-Feb;23(1):179-90. PubMed PMID: 16644618.
31 https://examine.com/supplements/vitamin-c/
32 Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. Nutrients. 2017;9(8):866. doi:10.3390/nu9080866.
33 https://www.veinvascular.com/vein/vitamins-good-veins/
34 Carr AC, Vissers MCM. Synthetic or Food-Derived Vitamin C—Are They Equally Bioavailable? Nutrients. 2013;5(11):4284-4304. doi:10.3390/nu5114284.
35 MJ Martinez-Zapata, et al. Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
36 MJ Martinez-Zapata, et al. Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
37 Y Tsouderos, Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg, Zeitschrift Fur Kardiologie, 1991; 80 Suppl 7:95-101
38 M Duchene et al, Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg, International Angiology, Apr-Jun 1988; 7(2): 25-32
39 Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009 Jul;7(3):303-8. Review. PubMed PMID: 19601855.
40 Diosmin. Monograph, Alt. Medicine Review, 2004; 9(3): 308-11
41 MJ Martinez-Zapata, et al. Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
42 Y Tsouderos, Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg, Zeitschrift Fur Kardiologie, 1991; 80 Suppl 7:95-101
43 M Duchene et al, Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg, International Angiology, Apr-Jun 1988; 7(2): 25-32
44 Z Maksimovic et al, Medicamentous treatment of chronic venous insufficiency using semisynthetic diosmin – a  prospective study, Acta Chirurgica Iugoslavica, 2008; 55(4):53-9

Home

DISCLAIMER: Talk to your doctor or health care provider to determine if Oraescin™ is right for you and is safe to take with your medications. Do not start or stop any prescribed medication or treatment without first consulting your doctor or health care provider.